藥易購(300937.SZ):IPO擬發行2391.67萬股 1月14日定價、18日申購
格隆匯1月8日丨藥易購(300937.SZ)披露首次公開發行股票並在創業板上市發行安排及初步詢價公吿,此次擬公開發行股票2391.6671萬股,佔發行後公司總股本的25.00%,發行後總股本為9566.6682萬股;全部為公開發行新股,不進行老股發售。
初始戰略配售發行數量為119.5833萬股,約佔此次發行數量的5.00%。回撥機制啟動前,網下初始發行數量為1590.4838萬股,約佔扣除初始戰略配售數量後發行數量的70.00%;網上初始發行數量為681.60萬股,約佔扣除初始戰略配售數量後發行數量的30.00%。
初步詢價時間為2021年1月13日的9:30-15:00,1月14日確定發行價格,1月15日網上路演,1月18日網上申購配號,1月22日刊登《發行結果公吿》。公吿顯示,公司網上、網下發行申購日為1月18日,1月20日將公佈中籤結果。
發行人股票簡稱為“藥易購”,股票代碼為“300937”,該代碼同時用於此次發行的初步詢價、網下及網上發行。根據《上市公司行業分類指引》(2012年修訂),發行人所屬行業為“F批發和零售業”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.